Fuel Tech And 2 Other Promising Penny Stocks For Consideration
The U.S. stock market has recently faced turbulence, with major indices like the Dow Jones and Nasdaq experiencing declines amid renewed trade tensions and economic uncertainty. Despite these challenges, investors continue to explore diverse opportunities, including those presented by penny stocks. Although often associated with smaller or newer companies, penny stocks can offer significant potential for growth when backed by strong financials and solid business fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
SideChannel (OTCPK:SDCH)
$0.0456
$12.02M
★★★★★★
Perfect (NYSE:PERF)
$1.85
$182.31M
★★★★★★
WM Technology (NasdaqGS:MAPS)
$1.02
$176.59M
★★★★★★
Global Mofy AI (NasdaqCM:GMM)
$2.93
$54.16M
★★★★★☆
Flexible Solutions International (NYSEAM:FSI)
$4.38
$55.02M
★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)
$2.48
$87.41M
★★★★★★
Table Trac (OTCPK:TBTC)
$4.51
$21.81M
★★★★★★
BAB (OTCPK:BABB)
$0.847
$5.9M
★★★★★★
Lifetime Brands (NasdaqGS:LCUT)
$3.21
$70.83M
★★★★★☆
New Horizon Aircraft (NasdaqCM:HOVR)
$0.8462
$28.25M
★★★★★★
Click here to see the full list of 732 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Fuel Tech, Inc. specializes in developing and commercializing technologies for air pollution control, process optimization, and water treatment, with a market cap of $49.13 million.
Operations: Fuel Tech, Inc. has not reported any specific revenue segments.
Market Cap: $49.13M
Fuel Tech, Inc., with a market cap of US$49.13 million, remains debt-free and has not significantly diluted shareholders over the past year. The company reported Q1 2025 sales of US$6.38 million but incurred a net loss of US$0.739 million, highlighting ongoing profitability challenges despite reducing losses by 44.5% annually over five years. Recent air pollution control orders totaling approximately US$4 million from customers in the U.S., Europe, and Japan indicate steady demand for its technologies. Fuel Tech's experienced management team and board contribute to its operational stability while it maintains a cash runway exceeding three years based on current free cash flow trends.
Dive into the specifics of Fuel Tech here with our thorough balance sheet health report.
Examine Fuel Tech's earnings growth report to understand how analysts expect it to perform.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: I-Mab is a biotech company that develops immuno-oncology agents for cancer treatment in the United States, with a market cap of $77.02 million.
Operations: I-Mab has not reported any specific revenue segments.
Market Cap: $77.02M
I-Mab, with a market cap of US$77.02 million, is pre-revenue and currently unprofitable but has reduced losses over the past five years. The company recently reported a Q1 2025 net loss of US$3.15 million, significantly down from the previous year's loss. Despite its financial challenges, I-Mab remains debt-free with short-term assets exceeding liabilities and holds sufficient cash for over three years based on current free cash flow. However, it faces potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement but is actively working on regaining compliance by September 2025.
Unlock comprehensive insights into our analysis of I-Mab stock in this financial health report.
Gain insights into I-Mab's outlook and expected performance with our report on the company's earnings estimates.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company in the United States with a market cap of $77.16 million.
Operations: Alto Neuroscience, Inc. has not reported any revenue segments.
Market Cap: $77.16M
Alto Neuroscience, Inc., with a market cap of US$77.16 million, is pre-revenue and unprofitable, reporting a Q1 2025 net loss of US$15.17 million. Despite financial challenges, it has strong liquidity with short-term assets of US$163.5 million exceeding liabilities and more cash than debt. The company recently showcased significant advancements in EEG-based biomarkers for predicting placebo responses in MDD trials at the SOBP Annual Meeting, which could enhance trial precision and reduce variability. However, earnings are forecast to decline over the next three years without expected profitability during this period.
Get an in-depth perspective on Alto Neuroscience's performance by reading our balance sheet health report here.
Explore Alto Neuroscience's analyst forecasts in our growth report.
Embark on your investment journey to our 732 US Penny Stocks selection here.
Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:FTEK NasdaqGM:IMAB and NYSE:ANRO.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Worried about a stock market crash? The Big Short's Michael Burry was…
The UK and US stock markets are once again approaching all-time highs. Markets have truly rebounded since Trump shocked the world with his trade policy. However, this rebound concerns me. These stock markets are trading near all-time highs despite a huge increase in the average effective US tariff, despite worsening geopolitical tensions, and despite sovereign debt concerns. Personally, I'm not sure investors have truly factored in the full impact of recent tariff increases on corporate earnings. Over the past year, average effective tariff rates have risen significantly, reaching levels not seen since the late 1930s. Under the Biden Administration, the average effective tariff rate was around 2.5%-2.7%. In May, that figure had risen to almost 20%. These tariffs have introduced new costs for businesses that rely on international supply chains. However, I just don't believe we've really seen the impact of them yet. After all, 'Liberation Day' took place at the beginning of Q2, and we're still in Q2. The full earnings impact of these tariffs is expected to become more visible in the second half of 2025, as companies report on their financial results and adjust to the new cost structures. Michael Burry, best known for predicting and profiting from the 2008 subprime mortgage crisis — a story retold in The Big Short — sold nearly all positions at Scion Asset Management in the quarter ending 31 March 2025. This move, alongside concentrated bearish bets through put options — bets that a stock will go down — on major tech and Chinese stocks, seemingly reflected his conviction that the market was sinking. Burry's only notable long was Estée Lauder, suggesting a defensive stance. However, 13F filings only show holdings as of 31 March, so his actions after that date remain unknown. As we know, the market slumped in early April but has since recovered. Within this context, I'm increasing looking at defensive options. I could look at farming stocks like Pilgrim's Pride, for example, which could outperform in a downturn. However, one option closer to home is the National Grid (LSE:NG.). The company recently reported strong financial results for the fiscal year 2025, with statutory and underlying pre-tax profit up 20%. The company is also investing heavily in its infrastructure, with a capital expenditure plan of £10bn aimed at modernising the energy grid and supporting the transition to renewable energy sources. This investment is part of a broader strategy to expand its regulated asset base, which is expected to grow by around 10% annually over the next few years. It does, however, introduce additional execution risk. Net debt is already £47.5bn — very sizeable. It's also not particularly cheap on face value. The stock trades at 14 times forward earnings, which may be a little demanding when we consider debt is on par with market capitalisation. Nonetheless, the forward dividend looks strong at 4.6%. The National Grid is not a stock I'd normally watch, but given my concerns about the potential overheating of the market, it's something I'm adding to my watchlist. It may be worth considering. The post Worried about a stock market crash? The Big Short's Michael Burry was… appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended National Grid Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
6 hours ago
- Wall Street Journal
Dow, S&P 500, Nasdaq All Positive on the Year Once Again
All three major U.S. stock indexes closed in positive year-to-date territory simultaneously for the first time since Feb. 21. The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average all rose by 1%, or more, during Friday's trading. Stocks have been volatile through weeks of tariff news, but have recovered losses from recent months. This year, the S&P 500 is up 2%, the Nasdaq is up 1.1% and the Dow is up 0.5%, according to Dow Jones Market Data.
Yahoo
8 hours ago
- Yahoo
Inside key meeting to remove Trump tariffs
Trade Minister Don Farrell has detailed the discussion he had with his US counterpart Jamieson Greer, revealing he had the 'greatest confidence' in Anthony Albanese during an expected meeting with Donald Trump next weekend. Senator Farrell spoke to the US Trade Representative while in Paris last week and characterised the talk as 'friendly'. Despite this, he maintained the tariffs were 'simply unjustified', highlighting Australia's trade surplus with the US. Figures indicate Australia buys about $70bn worth of goods from the US, compared to the $30bn of exports Australia sells to America. 'It wasn't a difficult discussion in terms of the relationship between us, and I am certainly of the view that we have the opportunity to continue to talk with Jamieson and Commerce Secretary Lutnick to put our case across,' he said. Senator Farrell also said he was still determined to get the trade barriers slashed. 'It's only by open discussion, honest discussion, with our allies in the United States that I think we can do that, but I certainly haven't given up on the prospect of getting these tariffs removed,' he said. 'And every opportunity I get, I'll continue to pursue that argument with the United States.' However, Senator Farrell said the decision will be ultimately made by Donald Trump, putting increased pressure on Mr Albanese's upcoming meeting with the US President. He said that while there were a 'range of ways' in which Australia communicates with the US, the 'most important … relationship between our prime minister and the president of the United States'. 'Look every meeting, I think, between an Australian Prime Minister and the US president will always be a critical meeting and I have the greatest confidence in our prime minister to push the Australian point of view on this.' The trade barriers currently include a 50 per cent levy on steel, a 25 per cent tariffs on aluminium and a blanket 10 per cent on other goods. While Mr Albanese maintained he won't compromise on Australia's biosecurity, he hinted Australia could review current settings which don't allow the US to import beef which originates from Canada and Mexico. Mr Albanese has also ruled out changes to the Pharmaceuticals Benefit Scheme, News Media Bargaining code and incoming ban on social media for under-16s, while highlighting Australia's critical minerals industry as a potential bargaining chip. 'If things can be sorted out in a way that protects our biosecurity – of course, we don't just say no, we don't want imports in here for the sake of it,' he told ABC radio on Friday. 'But our first priority is biosecurity and there'll be no compromise on that.' Mr Albanese said Australia would not have a 'subservient relationship to any nation'. 'We're a sovereign nation that stand on our own two feet,' he said. Senator Farrell also said he was 'confident' Australia can secure a new trade deal with the European Union, with EU President Ursula von der Leyen expected to visit Australia in July or August. 'We've got lots of things that we can sell to the to the Europeans. I believe now that there's an appetite to reach an agreement on both sides,' he said. 'The world has changed, those countries that believe in free and fair trade have to work together.'
